WHO ICTRP trial
Combined corticosteroid and long-acting beta-agonist versus corticosteroid for…
ACTRN12609000850279 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12609000850279 |
|---|---|
| Public title | Combined corticosteroid and long-acting beta-agonist versus corticosteroid for moderate/severe chronic obstructive pulmonary disease. A double blind, randomized, multicenter, phase III study. |
| Scientific title | In adults with Chronic Obstructive Pulmonary Disease (COPD), is corticosteroid combined with long-acting beta-agonist effective in forced expiratory volume in one second (FEV1) values, as compared to corticosteroid? |
| Primary sponsor | Aché Laboratories |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Brazil |
| Conditions | COPD (Chronic obstructive pulmonary disease); COPD (Chronic obstructive pulmonary disease);Respiratory - Chronic obstructive pulmonary disease |
| Interventions | Two arms: 1)Fluticasone 500 micrograms +Formoterol 12 micrograms, twice a day, for 12 weeks; capsule for inhalation 2)Fluticasone 500 micrograms, twice a day, for 12 weeks; capsule for inhalation |
| Registration date | Jan 10, 2009 |
| Target size | 136 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: